Specific Wnt ligands and receptors are found to be overexpressed in many tumors; monoclonal antibodies developed against Wnt-1 and Wnt-2 demonstrate Wnt inhibition leading to tumor suppression in melanoma, sarcoma, colorectal cancers, non-small cell lung carcinoma, and mesothelioma [25, 26]. Here, WNT2 is linked to sarcoma.